中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

60 records (took 0.022 seconds)

    44.
    发明专利
    未知

    公开(公告)号：AT496142T

    公开(公告)日：2011-02-15

    申请号：AT05721540

    申请日：2005-03-18

    Applicant: ONCOTHERAPY SCIENCE INC

    Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    IPC: C12Q1/68 ,  A61K31/731

    Abstract: Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1.

    45.
    发明专利
    未知

    公开(公告)号：AT483979T

    公开(公告)日：2010-10-15

    申请号：AT05770407

    申请日：2005-08-09

    Applicant: ONCOTHERAPY SCIENCE INC

    Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    IPC: G01N33/574

    Abstract: The present invention provides compositions and methods for identifying compounds for treating cancer as well as methods for predicting a prognosis of cancer. In particular, the present invention provides methods and kits for identifying inhibitors of the interaction between ANLN and RhoA which find utility in the treatment and prevention of cancer, particularly lung cancers such as non-small cell lung cancer (NSCLC). Also disclosed herein are compositions for treating or preventing cancer identified by the screening method of the present invention and methods of using same in the treatment and prevention of cancer.

    C6ORF167 PEPTIDES AND VACCINES CONTAINING THE SAME
    46.
    发明专利
    C6ORF167 PEPTIDES AND VACCINES CONTAINING THE SAME 未知

    公开(公告)号：CA2757210A1

    公开(公告)日：2010-10-07

    申请号：CA2757210

    申请日：2010-03-31

    Applicant: ONCOTHERAPY SCIENCE INC

    Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  TSUNODA TAKUYA ,  OHSAWA RYUJI ,  YOSHIMURA SACHIKO ,  WATANABE TOMOHISA

    IPC: C07K7/06 ,  A61K39/00 ,  A61P35/00 ,  C07K14/82 ,  C07K16/32 ,  C12N15/09 ,  C12Q1/04 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/574

    Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the C6orf167 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing peptides derived from C6orf167 or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from C6orf167, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

    OIP5 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS
    47.
    发明专利
    OIP5 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS 未知

    公开(公告)号：CA2735148A1

    公开(公告)日：2010-03-04

    申请号：CA2735148

    申请日：2009-08-24

    Applicant: ONCOTHERAPY SCIENCE INC

    Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  TOGASHI AKIRA

    IPC: C12N15/09 ,  C12Q1/68

    Abstract: The present invention relates to the roles played by OIP5 genes in lung and/or esophageal cancer carcinogenesis and features a method for treating and/or preventing lung and/or esophageal cancer by administering a double-stranded molecule against the OIP5 genes or a composition, vector or cell containing such a double-stranded molecule and antibody.The present invention also features methods for detecting and/or diagnosing lung and/or esophageal cancer, or assessing/determining the prognosis of and/or monitoring the efficacy of a cancer therapy in a patient with lung and/or esophageal cancer by detecting OIP5. Also, disclosed are methods of identifying compounds for treating and preventing cancer relating to OIP5.

    SYNGR4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS
    48.
    发明专利
    SYNGR4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS 未知

    公开(公告)号：CA2734979A1

    公开(公告)日：2010-03-04

    申请号：CA2734979

    申请日：2009-08-24

    Applicant: ONCOTHERAPY SCIENCE INC

    Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  TOGASHI AKIRA

    IPC: C12N15/09 ,  A61K31/713 ,  A61K48/00 ,  A61P35/00 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/53

    Abstract: The present invention relates to the roles played by the SYNGR4 genes in lung cancer carcinogenesis and features a method for treating or preventing lung cancer by administering a double-stranded molecule against one or more of the SYNGR4 genes or a composition, vector or cell containing such a double stranded molecule and antibody. The present invention also features methods for diagnosing lung cancer or assessing/determining the prognosis of a patient with lung cancer, especially NSCLC or SCLC, using one or more over-expressed genes selected from among SYNGR4. To that end, SYNGR4 may serve as a novel serological biomarker for lung cancer. Also, disclosed are methods of identifying compounds for treating and preventing lung cancer, using as an index their effect on the over-expression of one or more of SYNGR4 in the lung cancer.

    CANCER-RELATED GENES, CDCA5, EPHA7, STK31 AND WDHD1
    49.
    发明专利
    CANCER-RELATED GENES, CDCA5, EPHA7, STK31 AND WDHD1 未知

    公开(公告)号：CA2697517A1

    公开(公告)日：2009-03-05

    申请号：CA2697517

    申请日：2008-08-21

    Applicant: ONCOTHERAPY SCIENCE INC

    Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    IPC: C12N15/00 ,  A61K31/70 ,  A61K48/00 ,  A61P35/00

    Abstract: The invention features methods for detecting cancers, especially lung cancer and/or esophageal cancer, using over-expressed gene; CDCA5, EPHA7, STK31 or WDHD1 compared the normal organs. Also disclosed are methods of identifying compounds for treating and preventing cancers, based on the over-expression or the biological activity of CDCA5, EPHA7, STK31 or WDHD1 in the cancers, especially the interaction between EPHA7 and EGFR. Also, features are a method for treating cancers by administering a double-stranded molecule against CDCA5, EPHA7, STK31 or WDHD1 gene. The invention also features products, including the double-stranded molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods.

Patent Agency Ranking